Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Devalingam Mahalingam
Northwestern University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northwestern University
Chicago, Illinois, United States
Devalingam Mahalingam, MD, PhDRecruiting - Northwestern Medicine Orland Park
Orland Park, Illinois, United States
Devalingam Mahalingam, MD, PhDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Nov 2024
- Primary completion
- 10 May 2029
- Completion
- 10 May 2030
- Last update posted
- 12 Jun 2026
- Registered enrollment
- 64
- Registry id
- NCT06630416
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.